Divi's Laboratories share price
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Divi's Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2003
Last close ₹9,558.50up ₹53.00 (0.56%)BSE ₹9,561.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹9,505.50.
28 Oct: open ₹9,460.00, high ₹9,699.50, low ₹9,370.00
52-week range of traded prices to 28 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,53,748 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 86.75
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 15.14
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,45,04353.5% delivered
About Divi's Laboratories
Divi's Laboratories Limited makes active pharmaceutical ingredients (APIs, the substances in a medicine that produce its effect), intermediates (chemicals made on the way to an API) and nutraceutical ingredients for pharmaceutical and nutraceutical companies around the world.12 Its customers use them to make finished products such as medicines.3 It is headquartered in Hyderabad and focuses on export markets.45
Generic APIs are made in volumes from tens to thousands of metric tonnes a year, and the company says it is the world's largest maker of 10 of the 30 generic APIs it produces.67 Custom synthesis is contract manufacturing of complex APIs and intermediates for drug innovators, and the company says it works with 12 of the top 20 pharmaceutical companies worldwide.6 Nutraceuticals covers carotenoid ingredients and fat-soluble vitamins, such as astaxanthin, beta-carotene and lycopene, for food, beverage, dietary supplement and feed makers.8 Its wholly owned subsidiaries in New Jersey, USA and Basel, Switzerland market its nutraceutical ingredients.9
It manufactures at Unit 1 in Choutuppal near Hyderabad, Unit 2 in Visakhapatnam and Unit 3 in Kakinada.10 It was incorporated in 1990.11 The promoter and promoter group held 51.88% of the shares at the end of March 2026.12 Murali K. Divi is the Managing Director and Kiran S. Divi the Whole-time Director and Chief Executive Officer, while the chairman, Ramesh B. V. Nimmagadda, is an independent director.13
Divi's Laboratories key points
Results
- In the quarter to Jun 2026, consolidated total income was ₹3,144 crore against ₹2,529 crore a year earlier; profit before tax was ₹1,180 crore against ₹733 crore, and profit after tax ₹902 crore against ₹545 crore.14
- In the year to Mar 2026, consolidated total income was ₹11,067 crore, profit before tax ₹3,388 crore and profit after tax ₹2,568 crore.15
- On a standalone basis (the company without its subsidiaries), revenue from operations in the year to Mar 2026 was ₹10,388 crore, up 12.94%, and EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹3,920 crore.1617
Revenue mix
- Share of revenue by business18
Item quarter to Jun 2026 Custom Synthesis 60% Generics 40% - The nutraceutical business had revenue of ₹298 crore in the quarter to Jun 2026, against ₹250 crore a year earlier.19
- Share of standalone business from the top 520
Item year to Mar 2026 year to Mar 2025 Top 5 customers 51% 49% Top 5 products 48% 43%
Where revenue comes from
Plants and capacity
- The company states its manufacturing capacity as about 18,600 m3/KL (cubic metres, or kilolitres) for the year to Mar 2026.24
- On its earnings call of 1 Aug 2026, the company said its 3 units were running at about 80% to 85% of capacity.2526
- Unit 3 at Kakinada, operating since January 2025, is being scaled up in phases; it makes starting materials and intermediates in-house (backward integration) and frees capacity approved under good manufacturing practice (GMP) at the existing units.27
- The US Food and Drug Administration (US FDA) inspected the company's facility at Lingojigudem, Telangana from 10 Nov 2025 to 14 Nov 2025 and concluded with no Form 483 observations (a list of problems inspectors found).28
Research and development
- The company has 4 research and development (R&D) centres with about 700 scientists: Divi's Research Center in Hyderabad and process development centres at its manufacturing facilities.2930
- It holds 41 drug master files (DMFs, confidential dossiers on how an API is made) with the US FDA, 30 certificates of suitability with EDQM, 25 DMFs with Health Canada and 9 with Japan's PMDA, and has filed 44 patents for generic products.31
- In the year to Mar 2026 it set up a Peptide Centre of Excellence, for peptides (short chains of amino acids used as medicines).32
- On its earnings call of 1 Aug 2026, the company said it had filed about 4 DMFs with customers in the last few years, had supplied validation quantities, and that customers were qualifying them.33
Expansion and capital spending
- On its earnings call of 1 Aug 2026, the company said its 3 major capital expenditure programmes were nearing completion and that about 70% of their roughly ₹2,000 crore cost had been capitalised (moved from construction into fixed assets).3435
- Capital work in progress (assets still being built) stood at ₹2,034 crore at the end of June 2026, and ₹451 crore of assets were capitalised in the quarter.36
- On its earnings call of 1 Aug 2026, the company said it is adding capacity for SPPS (a method that builds peptides step by step on a support material), including a few more 3,000-litre SPPS units.3738
- On its earnings call of 1 Aug 2026, the company said it is signing multi-year contracts with 2 customers for iodine-based contrast media (substances that make body tissue show on scans) and expects to start supplying the second in the next few months.3940
What the company expects
Last updated
All 45 sources, each with its page
- 1. Annual report, 15 Jul 2026, page 28
- 2. Annual report, 15 Jul 2026, page 29
- 3. Annual report, 15 Jul 2026, page 43
- 4. Annual report, 15 Jul 2026, page 6
- 5. Annual report, 15 Jul 2026, page 49
- 6. Annual report, 15 Jul 2026, page 11
- 7. Annual report, 15 Jul 2026, page 48
- 8. Annual report, 15 Jul 2026, page 11
- 9. Annual report, 15 Jul 2026, page 64
- 10. Annual report, 15 Jul 2026, page 8
- 11. Annual report, 15 Jul 2026, page 28
- 12. Annual report, 15 Jul 2026, page 59
- 13. Annual report, 15 Jul 2026, page 27
- 14. Earnings call, 1 Aug 2026, page 6
- 15. Annual report, 15 Jul 2026, page 63
- 16. Annual report, 15 Jul 2026, page 50
- 17. Annual report, 15 Jul 2026, page 14
- 18. Earnings call, 1 Aug 2026, page 6
- 19. Earnings call, 1 Aug 2026, page 6
- 20. Annual report, 15 Jul 2026, page 50
- 21. Annual report, 15 Jul 2026, page 8
- 22. Annual report, 15 Jul 2026, page 8
- 23. Earnings call, 1 Aug 2026, page 6
- 24. Annual report, 15 Jul 2026, page 6
- 25. Earnings call, 1 Aug 2026, page 11
- 26. Earnings call, 1 Aug 2026, page 14
- 27. Annual report, 15 Jul 2026, page 64
- 28. Exchange filing, 14 Nov 2025, page 1
- 29. Annual report, 15 Jul 2026, page 6
- 30. Annual report, 15 Jul 2026, page 48
- 31. Annual report, 15 Jul 2026, page 49
- 32. Annual report, 15 Jul 2026, page 4
- 33. Earnings call, 1 Aug 2026, page 9
- 34. Earnings call, 1 Aug 2026, page 4
- 35. Earnings call, 1 Aug 2026, page 13
- 36. Earnings call, 1 Aug 2026, page 7
- 37. Earnings call, 1 Aug 2026, page 8
- 38. Earnings call, 1 Aug 2026, page 4
- 39. Earnings call, 1 Aug 2026, page 15
- 40. Earnings call, 1 Aug 2026, page 16
- 41. Earnings call, 1 Aug 2026, page 12
- 42. Earnings call, 1 Aug 2026, page 13
- 43. Earnings call, 1 Aug 2026, page 8
- 44. Exchange filing, 21 Mar 2026, page 1
- 45. Exchange filing, 21 Mar 2026, page 2
Results
Consolidated; ₹ crore.Divi's Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +16.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +26.8%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3,080 Crup 8.80%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹902 Crup 20.11%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 29.3%
Revenue by quarter
Peak revenue ₹3,080 Cr, quarter to Jun 2026; lowest ₹2,319 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 |
| Net profit | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 |
| Net margin | 21.8% | 25.4% | 25.6% | 22.6% | 25.4% | 22.4% | 26.5% | 29.3% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹10,560 Crup 12.82%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,568 Crup 17.21%
- Net margin
- 24.3%
Revenue by year
Peak revenue ₹10,560 Cr, year to Mar 2026; lowest ₹3,913 Cr, year to Mar 2018
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,106 | 3,913 | 4,946 | 5,394 | 6,969 | 8,960 | 7,768 | 7,845 | 9,360 | 10,560 |
| Net profit | 1,060 | 877 | 1,353 | 1,377 | 1,984 | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 |
| Net margin | 25.8% | 22.4% | 27.3% | 25.5% | 28.5% | 33.0% | 23.5% | 20.4% | 23.4% | 24.3% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients, which carries all its revenue.
Valuation
Today, against the company's own history.Divi's Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 98% of 2,478 trading days over the last 10 years.
LowestHighest
Its median49.34Industry median28.10
Price to book
At or below today's level on 99.7% of 1,983 trading days since Oct 2018.
LowestHighest
Its median9.62Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 10% of 2,478 trading days over the last 10 years.
LowestHighest
Its median0.61%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +3.5% | +17.2% | −12.2% | 0.5% |
| 3 years | +28.8% | +12.1% | +14.4% | 0.6% |
| 5 years | +11.1% | +5.3% | +4.9% | 0.7% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
410 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 127 of the 198 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 5 more funds filed their first portfolio on record, holding it.All 410 funds holding Divi's Laboratories
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 15
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 17
- AddedAdded. Funds that held more shares than at the end of the month before.
- 121
- CutCut. Funds that held fewer shares than at the end of the month before.
- 77
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 175
| Fund | |||
|---|---|---|---|
 SBI Large Cap FundSBI Mutual Fund | 20,32,024 | 3.61% | ₹1,888.1 Cr |
 HDFC Flexi Cap FundHDFC Mutual Fund | 18,93,863 | 1.62% | ₹1,759.7 Cr |
| SBI Aggressive Hybrid FundSBI Mutual Fund | 17,00,000 | 1.83% | ₹1,579.6 Cr |
| SBI Focused FundSBI Mutual Fund | 13,00,000 | 2.41% | ₹1,207.9 Cr |
 Axis ELSS Tax Saver FundAxis Mutual Fund | 8,93,550 | 2.74% | ₹830.2 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 8,88,857 | 0.81% | ₹825.9 Cr |
| Axis Large Cap FundAxis Mutual Fund | 8,56,121 | 2.72% | ₹795.5 Cr |
| SBI Multicap FundSBI Mutual Fund | 8,50,000 | 3.37% | ₹789.8 Cr |
| SBI Large & Midcap FundSBI Mutual Fund | 8,30,000 | 1.90% | ₹771.2 Cr |
 Nippon India Large Cap FundNippon India Mutual Fund | 8,00,190 | 1.45% | ₹743.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Divi's Laboratories insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 1 saleNo purchase₹17 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹17 Cr
- Directors and key managers0 purchases, 1 saleNo purchase₹0.32 CrNet−₹0.32 Cr2 off-market moves
- Others7 purchases, 8 sales₹2.71 Cr₹20 CrNet−₹17 Cr1 pledge created · 2 pledges released · 3 pledge filings of unclear kind · 5 off-market moves
- Employees: no market trade · 2 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Divi's Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Divi's Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,21,683 | 34.86 | 5.05 | +11.4% | +16.6% | 15.5% | 16.9% | 0.91% |
 Torrent PharmaceuticalsTORNTPHARM | 1,73,334 | 81.61 | 9.43 | +42.1% | −0.7% | 15.8% | 12.0% | 0.83% |
 Laurus LabsLAURUSLABS | 1,17,891 | 107.82 | 22.24 | +22.6% | +114.9% | 22.4% | 19.8% | 0.09% |
 Zydus LifesciencesZYDUSLIFE | 1,17,257 | 25.98 | 4.33 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,11,463 | 39.81 | 2.87 | −3.5% | −51.5% | 7.5% | 6.0% | 0.60% |
 CiplaCIPLA | 1,10,323 | 38.08 | 3.12 | −0.7% | −46.8% | 8.5% | 9.7% | 0.95% |
 Mankind PharmaMANKIND | 1,02,848 | 45.74 | 5.85 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 94,638 | 25.49 | 2.50 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Divi's Laboratories dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹30.00 a share, in 5 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹30.00 |
| 25 Jul 2025 | Final | ₹30.00 |
| 2 Aug 2024 | Final | ₹30.00 |
| 11 Aug 2023 | Final | ₹30.00 |
| 11 Aug 2022 | Final | ₹30.00 |
| 17 Aug 2021 | Final | ₹20.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Divi's Laboratories announcements
Oct 2026
22 Oct · Board meeting
Aug 2026
1 Aug · Results
Jul 2026
31 Jul · Retirement
24 Jul · Analysts
Divi's Laboratories share price by year
Each calendar year to 2025.Divi's Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 6,392.50 | +4.8% | 6,983.50 | 5,258.95 |
| 2024 | 6,098.80 | +56.2% | 6,256.50 | 3,367.85 |
| 2023 | 3,903.90 | +14.4% | 3,939.95 | 2,750.85 |
| 2022 | 3,413.20 | −27.0% | 4,651.25 | 3,265.95 |
| 2021 | 4,678.20 | +21.8% | 5,372.15 | 3,272.90 |
| 2020 | 3,841.90 | +108.1% | 3,841.90 | 1,805.25 |
| 2019 | 1,845.80 | +24.5% | 1,860.65 | 1,437.90 |
| 2018 | 1,482.65 | +35.0% | 1,562.25 | 990.80 |
| 2017 | 1,098.35 | +40.1% | 1,123.45 | 545.30 |
| 2016 | 783.70 | −32.1% | 1,347.85 | 762.30 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 9,090.00 | 9,505.50 | 9,067.00 | 9,505.50 | 9,359.81 | 8,02,780 | 51.3% |
| 26 Oct 2026 | 8,900.00 | 9,080.00 | 8,860.00 | 9,050.00 | 8,986.49 | 5,76,071 | 63.6% |
| 23 Oct 2026 | 9,165.00 | 9,175.50 | 8,797.00 | 8,950.00 | 8,904.51 | 6,20,261 | 60.6% |
| 22 Oct 2026 | 9,114.00 | 9,190.00 | 9,006.50 | 9,162.00 | 9,103.23 | 10,40,584 | 76.1% |
| 21 Oct 2026 | 9,190.00 | 9,243.00 | 9,041.00 | 9,190.00 | 9,130.61 | 6,85,478 | 70.9% |
| 19 Oct 2026 | 9,191.50 | 9,323.50 | 9,045.00 | 9,087.00 | 9,175.76 | 4,48,972 | 54.0% |
| 16 Oct 2026 | 9,030.50 | 9,248.00 | 8,985.50 | 9,144.50 | 9,099.20 | 7,78,528 | 61.8% |
| 15 Oct 2026 | 9,085.00 | 9,124.50 | 8,950.00 | 9,030.00 | 9,036.58 | 6,45,244 | 65.6% |
| 14 Oct 2026 | 9,315.00 | 9,315.00 | 8,937.50 | 9,023.00 | 9,069.38 | 9,92,022 | 68.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 23 Dec 2016 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 23 Sep 2015 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 30 Jul 2009 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 3 Aug 2007 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- DIVISLAB
- BSE code
- 532488
- ISIN
- INE361B01024
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.divislaboratories.com
- CIN
- L24110TG1990PLC011854
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1990
- Registered office
- 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad 500032, Telangana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty Next 50, Nifty 100, BSE 100, Nifty 200, BSE 200, Nifty 500